Details of the Drug

General Information of Drug (ID: DMK7F9S)

Drug Name

Amitriptyline

Synonyms

Adepress; Adepril; Amitril; Amitriprolidine; Amitriptilina; Amitriptylin; Amitriptylinum; Amitryptiline; Amitryptyline; Amytriptiline; Amytriptylin; Damilan; Damilen; Damitriptyline; Elanil; Elavil; Flavyl; Lantron; Laroxil; Laroxyl; Proheptadiene; Redomex; Sarotex; Seroten; Sylvemid; Triptanol; Triptilin; Triptisol; Tryptanol; Amitriptilina [Italian]; Amitriptylin [German]; MK 230; N 750; TP0; Amitriptilina [INN-Spanish]; Amitriptyline (INN); Amitriptyline [INN:BAN]; Amitriptylinum [INN-Latin]; Elavil (TN); Laroxyl (TN); Ro 4-1575; [3-(10,11-Dihydro-dibenzo[a,d]cyclohepten-5-ylidene)-propyl]-dimethyl-amine; 10,11-Dihydro-5-(gamma-dimethylaminopropylidene)-5H-dibenzo(a,d)cycloheptene; 10,11-Dihydro-N,N-dimethyl-5H-dibenzo(a,d)heptalene-delta(5),gamma-propylamine; 10,11-dihydro-5-(gamma-dimethylaminopropylidene)-5H-dibenzo[a,d]cycloheptene; 3-(10,11-Dihydro-5H-dibenzo(a,d)cyclohepten-5-yliden)-N,N-dimethylpropylamin; 3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N,N-dimethylpropan-1-amine; 5-(3'-Dimethylaminopropylidene)-dibenzo-(a,d)(1,4)-cycloheptadiene; 5-(3'-Dimethylaminopropylidene)-dibenzo-[a,d][1,4]-cycloheptadiene; 5-(3-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptatriene; 5-(3-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene; 5-(3-Dimethylaminopropylidene)-5H-dibenzo[a,d]-10,11-dihydrocycloheptene; 5-(3-dimethylaminopropylidene)dibenzo[a,d][1,4]-cycloheptadiene; 5-(gamma-Dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene; 5-(gamma-Dimethylaminopropylidene)-5H-Dibenzo[a,d][1,4]cycloheptadiene; 5-(gamma-Dimethylaminopropylidene)-5H-dibenzo(a,d)(1,4)cycloheptadiene; 5-(gamma-Dimethylaminopropylidene)-5H-dibenzo[a,d]10,11-dihydrocycloheptene; 5-(gamma-Dimethylaminopropylidine)-5H-dibenzo(a,d)(1,4)cycloheptadiene

Indication

Disease Entry	ICD 11	Status	REF
Depression	6A70-6A7Z	Approved	[1]
Pain	MG30-MG3Z	Approved	[2]
Mixed anxiety and depressive disorder	N.A.	Investigative	[2]
Sleep disorder, initiating and maintaining sleep	N.A.	Investigative	[2]
------------------------------------------------------------------------------------

Therapeutic Class

Analgesics

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

277.4

Logarithm of the Partition Coefficient (xlogp)

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Bioavailability: The bioavailability of drug is 100% [4]
Clearance: The sytemic clearance of drug is 39.24 +/- 10.18 L/h [5]
Elimination: Virtually the entire dose is excreted as glucuronide or sulfate conjugate of metabolites, with approximately 2% of unchanged drug appearing in the urine []
Half-life: The concentration or amount of drug in body reduced by one-half in 25 hours []
Metabolism: The drug is metabolized via the demethylation (CYP2C19, CYP3A4) as well as hydroxylation (CYP2D6) followed by conjugation with glucuronic acid []
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 15.4494 micromolar/kg/day [6]
Unbound Fraction: The unbound fraction of drug in plasma is 0.07% [7]
Vd: The volume of distribution (Vd) of drug is 1221 L +/- 280 L [5]
Water Solubility: The ability of drug to dissolve in water is measured as 1000 mg/mL [3]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Amitriptyline	rs2032583	ABCB1	OTEJROBO	[8]
Arrhythmia	Not Available	CYP2D6	OTZJC802	[9]
Atrioventricular block	Not Available	CYP3A4	OTQGYY83	[9]
Haemorrhage	Not Available	CYP2C19	OTFMJYYE	[9]
-----------

Chemical Identifiers

Formula: C20H23N
IUPAC Name: N,N-dimethyl-3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenylidene)propan-1-amine
Canonical SMILES: CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31
InChI: InChI=1S/C20H23N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-12H,7,13-15H2,1-2H3
InChIKey: KRMDCWKBEZIMAB-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 2160
ChEBI ID: CHEBI:2666
CAS Number: 50-48-6
DrugBank ID: DB00321
TTD ID: D0Y5UG
VARIDT ID: DR00470
INTEDE ID: DR0095
ACDINA ID: D00032

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Norepinephrine transporter (NET)	TTAWNKZ	SC6A2_HUMAN	Inhibitor	[10]
Serotonin transporter (SERT)	TT3ROYC	SC6A4_HUMAN	Inhibitor	[10]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[11]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[12]
Cytochrome P450 2E1 (CYP2E1)	DEVDYN7	CP2E1_HUMAN	Substrate	[13]
Cytochrome P450 2D6 (CYP2D6)_{Main DME}	DECB0K3	CP2D6_HUMAN	Substrate	[12]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[14]
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DEYGVN4	UD11_HUMAN	Substrate	[15]
Mephenytoin 4-hydroxylase (CYP2C19)_{Main DME}	DEGTFWK	CP2CJ_HUMAN	Substrate	[16]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[17]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[18]
Cytochrome P450 2B6 (CYP2B6)	DEPKLMQ	CP2B6_HUMAN	Substrate	[19]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Substrate	[20]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Drug Response	[8]
Cytochrome P450 2C19 (CYP2C19)	OTFMJYYE	CP2CJ_HUMAN	Drug Response	[9]
Cytochrome P450 2D6 (CYP2D6)	OTZJC802	CP2D6_HUMAN	Drug Response	[9]
Cytochrome P450 3A4 (CYP3A4)	OTQGYY83	CP3A4_HUMAN	Drug Response	[9]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Depression

ICD Disease Classification

6A70-6A7Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Serotonin transporter (SERT)	DTT	SLC6A4	8.76E-01	7.18E-05	6.19E-04
P-glycoprotein 1 (ABCB1)	DTP	P-GP	6.54E-01	1.95E-01	4.04E-01
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DME	UGT1A1	4.53E-01	4.14E-02	1.83E-01
Cytochrome P450 2E1 (CYP2E1)	DME	CYP2E1	9.45E-02	-1.86E-01	-9.83E-01
Cytochrome P450 2C8 (CYP2C8)	DME	CYP2C8	5.57E-01	-7.89E-02	-7.93E-01
Cytochrome P450 2B6 (CYP2B6)	DME	CYP2B6	4.32E-01	4.39E-02	4.30E-01
Cytochrome P450 1A2 (CYP1A2)	DME	CYP1A2	8.46E-01	-6.63E-03	-4.49E-02
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	9.57E-01	9.43E-03	1.29E-01
Mephenytoin 4-hydroxylase (CYP2C19)	DME	CYP2C19	9.62E-01	2.57E-02	1.10E-01
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	8.70E-01	2.98E-02	1.22E-01
Cytochrome P450 2C9 (CYP2C9)	DME	CYP2C9	2.35E-01	2.78E-02	2.09E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	1.76E-01	1.26E-01	8.27E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Amitriptyline

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Trimipramine	DM1SC8M	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and Trimipramine.	Depression [6A70-6A7Z]	[21]
Imipramine	DM2NUH3	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and Imipramine.	Depression [6A70-6A7Z]	[21]
Fluoxetine	DM3PD2C	Major	Decreased metabolism of Amitriptyline caused by Fluoxetine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[22]
Nortriptyline	DM4KDYJ	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and Nortriptyline.	Depression [6A70-6A7Z]	[21]
Vilazodone	DM4LECQ	Major	Additive serotonergic effects by the combination of Amitriptyline and Vilazodone.	Depression [6A70-6A7Z]	[23]
Nefazodone	DM4ZS8M	Major	Additive serotonergic effects by the combination of Amitriptyline and Nefazodone.	Depression [6A70-6A7Z]	[23]
Paroxetine	DM5PVQE	Major	Decreased metabolism of Amitriptyline caused by Paroxetine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[24]
Selegiline	DM6034S	Major	Additive serotonergic effects by the combination of Amitriptyline and Selegiline.	Depression [6A70-6A7Z]	[25]
Vortioxetine	DM6F1PU	Major	Additive serotonergic effects by the combination of Amitriptyline and Vortioxetine.	Depression [6A70-6A7Z]	[23]
Duloxetine	DM9BI7M	Major	Additive serotonergic effects by the combination of Amitriptyline and Duloxetine.	Depression [6A70-6A7Z]	[23]
Isocarboxazid	DMAF1NB	Major	Additive serotonergic effects by the combination of Amitriptyline and Isocarboxazid.	Depression [6A70-6A7Z]	[25]
Milnacipran	DMBFE74	Major	Additive serotonergic effects by the combination of Amitriptyline and Milnacipran.	Depression [6A70-6A7Z]	[23]
Escitalopram	DMFK9HG	Major	Increased risk of prolong QT interval by the combination of Amitriptyline and Escitalopram.	Depression [6A70-6A7Z]	[26]
Tranylcypromine	DMGB5RE	Major	Additive serotonergic effects by the combination of Amitriptyline and Tranylcypromine.	Depression [6A70-6A7Z]	[25]
Desvenlafaxine	DMHD4PE	Major	Additive serotonergic effects by the combination of Amitriptyline and Desvenlafaxine.	Depression [6A70-6A7Z]	[23]
OPC-34712	DMHG57U	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and OPC-34712.	Depression [6A70-6A7Z]	[21]
Phenelzine	DMHIDUE	Major	Additive serotonergic effects by the combination of Amitriptyline and Phenelzine.	Depression [6A70-6A7Z]	[25]
Clomipramine	DMINRKW	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and Clomipramine.	Depression [6A70-6A7Z]	[21]
Trazodone	DMK1GBJ	Major	Additive serotonergic effects by the combination of Amitriptyline and Trazodone.	Depression [6A70-6A7Z]	[23]
Amoxapine	DMKITQE	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and Amoxapine.	Depression [6A70-6A7Z]	[21]
Mirtazapine	DML53ZJ	Major	Additive serotonergic effects by the combination of Amitriptyline and Mirtazapine.	Depression [6A70-6A7Z]	[23]
Protriptyline	DMNHTZI	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and Protriptyline.	Depression [6A70-6A7Z]	[21]
Doxepin	DMPI98T	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and Doxepin.	Depression [6A70-6A7Z]	[21]
Maprotiline	DMPWB7T	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and Maprotiline.	Depression [6A70-6A7Z]	[21]
-----------


⏷ Show the Full List of 24 DDI Information of This Drug

Coadministration of a Drug Treating the Disease Different from Amitriptyline (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Methylene blue	DMJAPE7	Major	Additive serotonergic effects by the combination of Amitriptyline and Methylene blue.	Acquired methaemoglobinaemia [3A93]	[25]
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Amitriptyline and Ivosidenib.	Acute myeloid leukaemia [2A60]	[27]
Midostaurin	DMI6E0R	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Midostaurin.	Acute myeloid leukaemia [2A60]	[28]
Idarubicin	DMM0XGL	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Idarubicin.	Acute myeloid leukaemia [2A60]	[28]
Daunorubicin	DMQUSBT	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Daunorubicin.	Acute myeloid leukaemia [2A60]	[28]
Arn-509	DMT81LZ	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Arn-509.	Acute myeloid leukaemia [2A60]	[29]
Gilteritinib	DMTI0ZO	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Gilteritinib.	Acute myeloid leukaemia [2A60]	[30]
Oliceridine	DM6MDCF	Moderate	Additive CNS depression effects by the combination of Amitriptyline and Oliceridine.	Acute pain [MG31]	[31]
Scopolamine	DMOM8AL	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and Scopolamine.	Addictive disorder [6C50-6C5Z]	[21]
Terfenadine	DM4KLPT	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Terfenadine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[28]
Mepyramine	DMB4SFH	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[32]
Phenyltoloxamine	DMKAEQW	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[32]
Tripelennamine	DMZBU15	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and Tripelennamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[21]
Tacrine	DM51FY6	Moderate	Antagonize the effect of Amitriptyline when combined with Tacrine.	Alzheimer disease [8A20]	[33]
Memantine	DMD9WSC	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and Memantine.	Alzheimer disease [8A20]	[21]
Galantamine	DMEO794	Moderate	Antagonize the effect of Amitriptyline when combined with Galantamine.	Alzheimer disease [8A20]	[33]
Rivastigmine	DMG629M	Moderate	Antagonize the effect of Amitriptyline when combined with Rivastigmine.	Alzheimer disease [8A20]	[33]
Donepezil	DMIYG7Z	Moderate	Antagonize the effect of Amitriptyline when combined with Donepezil.	Alzheimer disease [8A20]	[33]
Metronidazole	DMTIVEN	Minor	Increased risk of prolong QT interval by the combination of Amitriptyline and Metronidazole.	Amoebiasis [1A36]	[34]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Amitriptyline and Ivabradine.	Angina pectoris [BA40]	[29]
Bepridil	DM0RKS4	Major	Increased risk of prolong QT interval by the combination of Amitriptyline and Bepridil.	Angina pectoris [BA40]	[35]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Amitriptyline and Dronedarone.	Angina pectoris [BA40]	[28]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Amitriptyline and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[36]
Buspirone	DMBS632	Major	Additive serotonergic effects by the combination of Amitriptyline and Buspirone.	Anxiety disorder [6B00-6B0Z]	[23]
Hydroxyzine	DMF8Y74	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and Hydroxyzine.	Anxiety disorder [6B00-6B0Z]	[21]
Clobazam - Lundbeck	DMW1OQ0	Moderate	Decreased metabolism of Amitriptyline caused by Clobazam - Lundbeck mediated inhibition of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[37]
Promazine	DMZAL7W	Moderate	Increased plasma concentrations of Amitriptyline and Promazine due to competitive inhibition of the same metabolic pathway.	Appearance/behaviour symptom [MB23]	[38]
Cilostazol	DMZMSCT	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Cilostazol.	Arterial occlusive disease [BD40]	[28]
Voriconazole	DMAOL2S	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Voriconazole.	Aspergillosis [1F20]	[28]
Methylphenidate	DM7SJD6	Moderate	Decreased metabolism of Amitriptyline caused by Methylphenidate.	Attention deficit hyperactivity disorder [6A05]	[39]
Desipramine	DMT2FDC	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[21]
Ofloxacin	DM0VQN3	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[40]
Ciprofloxacin XR	DM2NLS9	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Ciprofloxacin XR.	Bacterial infection [1A00-1C4Z]	[28]
Dalfopristin	DM4LTKV	Major	Decreased metabolism of Amitriptyline caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[41]
Sulfamethoxazole	DMB08GE	Minor	Increased risk of prolong QT interval by the combination of Amitriptyline and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[28]
Sparfloxacin	DMB4HCT	Major	Increased risk of prolong QT interval by the combination of Amitriptyline and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[40]
Linezolid	DMGFPU2	Major	Additive serotonergic effects by the combination of Amitriptyline and Linezolid.	Bacterial infection [1A00-1C4Z]	[42]
Gemifloxacin	DMHT34O	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[40]
Norfloxacin	DMIZ6W2	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[40]
Levofloxacin	DMS60RB	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[40]
Lomefloxacin	DMVRH9C	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[28]
Telithromycin	DMZ4P3A	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Telithromycin.	Bacterial infection [1A00-1C4Z]	[28]
Retigabine	DMGNYIH	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Retigabine.	Behcet disease [4A62]	[28]
Cariprazine	DMJYDVK	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and Cariprazine.	Bipolar disorder [6A60]	[21]
Loperamide	DMOJZQ9	Moderate	Additive antimotility effects by the combination of Amitriptyline and Loperamide.	Bowel habit change [ME05]	[43]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Eribulin.	Breast cancer [2C60-2C6Y]	[28]
Lapatinib	DM3BH1Y	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Lapatinib.	Breast cancer [2C60-2C6Y]	[28]
Alpelisib	DMEXMYK	Moderate	Increased metabolism of Amitriptyline caused by Alpelisib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[44]
Tamoxifen	DMLB0EZ	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Tamoxifen.	Breast cancer [2C60-2C6Y]	[28]
Toremifene	DMQYUWG	Major	Increased risk of prolong QT interval by the combination of Amitriptyline and Toremifene.	Breast cancer [2C60-2C6Y]	[28]
Grepafloxacin	DMGLX0T	Major	Increased risk of prolong QT interval by the combination of Amitriptyline and Grepafloxacin.	Bronchitis [CA20]	[40]
Sotalol	DML60TN	Major	Increased risk of prolong QT interval by the combination of Amitriptyline and Sotalol.	Cardiac arrhythmia [BC9Z]	[28]
Acetylcholine	DMDF79Z	Moderate	Antagonize the effect of Amitriptyline when combined with Acetylcholine.	Cataract [9B10]	[45]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[46]
Umeclidinium	DM4E8O9	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and Umeclidinium.	Chronic obstructive pulmonary disease [CA22]	[47]
Tiotropium	DMFDC0Q	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and Tiotropium.	Chronic obstructive pulmonary disease [CA22]	[47]
Ipratropium	DMFQ320	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and Ipratropium.	Chronic obstructive pulmonary disease [CA22]	[47]
Revefenacin	DMMP5SI	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and Revefenacin.	Chronic obstructive pulmonary disease [CA22]	[47]
Dihydrocodeine	DMB0FWL	Moderate	Additive serotonergic effects by the combination of Amitriptyline and Dihydrocodeine.	Chronic pain [MG30]	[31]
Levomilnacipran	DMV26S8	Major	Additive serotonergic effects by the combination of Amitriptyline and Levomilnacipran.	Chronic pain [MG30]	[23]
Oxaliplatin	DMQNWRD	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Oxaliplatin.	Colorectal cancer [2B91]	[28]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Amitriptyline and Olopatadine.	Conjunctiva disorder [9A60]	[48]
Mestranol	DMG3F94	Minor	Decreased metabolism of Amitriptyline caused by Mestranol.	Contraceptive management [QA21]	[49]
Halothane	DM80OZ5	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Halothane.	Corneal disease [9A76-9A78]	[28]
Alfentanil	DMVO0UB	Moderate	Additive serotonergic effects by the combination of Amitriptyline and Alfentanil.	Corneal disease [9A76-9A78]	[31]
Remifentanil	DMZTXCH	Moderate	Additive CNS depression effects by the combination of Amitriptyline and Remifentanil.	Corneal disease [9A76-9A78]	[31]
Probucol	DMVZQ2M	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Probucol.	Coronary atherosclerosis [BA80]	[28]
Methadone	DMTW6IU	Major	Increased risk of prolong QT interval by the combination of Amitriptyline and Methadone.	Cough [MD12]	[28]
Clofazimine	DMEBOFW	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Clofazimine.	Crohn disease [DD70]	[50]
Mifepristone	DMGZQEF	Major	Increased risk of prolong QT interval by the combination of Amitriptyline and Mifepristone.	Cushing syndrome [5A70]	[28]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Osilodrostat.	Cushing syndrome [5A70]	[29]
Ethanol	DMDRQZU	Moderate	Additive CNS depression effects by the combination of Amitriptyline and Ethanol.	Cystitis [GC00]	[51]
Hyoscyamine	DM804UR	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and Hyoscyamine.	Digestive system disease [DE2Z]	[21]
Mepenzolate	DM8YU2F	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and Mepenzolate.	Digestive system disease [DE2Z]	[21]
5-hydroxy-L-tryptophan	DMDWZGJ	Major	Additive serotonergic effects by the combination of Amitriptyline and 5-hydroxy-L-tryptophan.	Discovery agent [N.A.]	[52]
Oxybutynine	DMJPBAX	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and Oxybutynine.	Discovery agent [N.A.]	[21]
Tetrabenazine	DMYWQ0O	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[28]
Meclizine	DMS7T13	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and Meclizine.	Dizziness and giddiness [MB48]	[21]
Trihexyphenidyl	DMB19L8	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and Trihexyphenidyl.	Dystonic disorder [8A02]	[21]
Deutetrabenazine	DMUPFLI	Moderate	Additive CNS depression effects by the combination of Amitriptyline and Deutetrabenazine.	Dystonic disorder [8A02]	[53]
Fenfluramine	DM0762O	Moderate	Additive serotonergic effects by the combination of Amitriptyline and Fenfluramine.	Epilepsy/seizure [8A61-8A6Z]	[54]
Zonisamide	DM0DTF7	Major	Increased risk of hyperpyrexia by the combination of Amitriptyline and Zonisamide.	Epilepsy/seizure [8A61-8A6Z]	[55]
Oxcarbazepine	DM5PU6O	Moderate	Decreased metabolism of Amitriptyline caused by Oxcarbazepine mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[34]
Fosphenytoin	DMOX3LB	Moderate	Decreased metabolism of Amitriptyline caused by Fosphenytoin mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[56]
Carbamazepine	DMZOLBI	Moderate	Antagonize the effect of Amitriptyline when combined with Carbamazepine.	Epilepsy/seizure [8A61-8A6Z]	[57]
Diphenhydramine	DMKQTBA	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and Diphenhydramine.	Episodic vestibular syndrome [AB31]	[21]
Solifenacin	DMG592Q	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and Solifenacin.	Functional bladder disorder [GC50]	[21]
Mirabegron	DMS1GYT	Moderate	Decreased metabolism of Amitriptyline caused by Mirabegron mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[58]
Tolterodine	DMSHPW8	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and Tolterodine.	Functional bladder disorder [GC50]	[21]
Darifenacin	DMWXLYZ	Moderate	Decreased metabolism of Amitriptyline caused by Darifenacin mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[59]
Itraconazole	DMCR1MV	Moderate	Decreased metabolism of Amitriptyline caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[60]
Pentamidine	DMHZJCG	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Pentamidine.	Fungal infection [1F29-1F2F]	[28]
Terbinafine	DMI6HUW	Moderate	Decreased metabolism of Amitriptyline caused by Terbinafine mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[61]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Amitriptyline caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[60]
Propantheline	DM2EN6G	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and Propantheline.	Gastric ulcer [DA60]	[21]
Cimetidine	DMH61ZB	Moderate	Decreased metabolism of Amitriptyline caused by Cimetidine mediated inhibition of CYP450 enzyme.	Gastro-oesophageal reflux disease [DA22]	[62]
Cisapride	DMY7PED	Major	Increased risk of prolong QT interval by the combination of Amitriptyline and Cisapride.	Gastro-oesophageal reflux disease [DA22]	[28]
Sunitinib	DMCBJSR	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[28]
Acetazolamide	DM1AF5U	Minor	as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Amitriptyline caused by Acetazolamide mediated altered urine pH.	Glaucoma [9C61]	[63]
Isoflurophate	DMBSK7X	Moderate	Antagonize the effect of Amitriptyline when combined with Isoflurophate.	Glaucoma [9C61]	[45]
Brimonidine	DMQLT4N	Moderate	Additive CNS depression effects by the combination of Amitriptyline and Brimonidine.	Glaucoma [9C61]	[64]
Pilocarpine	DMV9ADG	Moderate	Antagonize the effect of Amitriptyline when combined with Pilocarpine.	Glaucoma [9C61]	[45]
Carvedilol	DMHTEAO	Moderate	Increased plasma concentrations of Amitriptyline and Carvedilol due to competitive inhibition of the same metabolic pathway.	Heart failure [BD10-BD1Z]	[56]
Procarbazine	DMIK367	Major	Additive serotonergic effects by the combination of Amitriptyline and Procarbazine.	Hodgkin lymphoma [2B30]	[25]
Fosamprenavir	DM4W9B3	Moderate	Decreased metabolism of Amitriptyline caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[65]
Fostemsavir	DM50ILT	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[66]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Amitriptyline caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[67]
Efavirenz	DMC0GSJ	Major	Increased risk of prolong QT interval by the combination of Amitriptyline and Efavirenz.	Human immunodeficiency virus disease [1C60-1C62]	[68]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Amitriptyline and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[69]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[28]
Amprenavir	DMLMXE0	Moderate	Decreased metabolism of Amitriptyline caused by Amprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[65]
Atazanavir	DMSYRBX	Moderate	Decreased metabolism of Amitriptyline caused by Atazanavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[65]
Ritonavir	DMU764S	Moderate	Decreased metabolism of Amitriptyline caused by Ritonavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[70]
Cinacalcet	DMCX0K3	Moderate	Decreased metabolism of Amitriptyline caused by Cinacalcet mediated inhibition of CYP450 enzyme.	Hyper-parathyroidism [5A51]	[34]
Verapamil	DMA7PEW	Moderate	Decreased metabolism of Amitriptyline caused by Verapamil mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[71]
Labetalol	DMK8U72	Moderate	Increased plasma concentrations of Amitriptyline and Labetalol due to competitive inhibition of the same metabolic pathway.	Hypertension [BA00-BA04]	[56]
Belladonna	DM2RBWK	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[21]
Propiomazine	DMKY8V1	Moderate	Increased plasma concentrations of Amitriptyline and Propiomazine due to competitive inhibition of the same metabolic pathway.	Insomnia [7A00-7A0Z]	[38]
ITI-007	DMUQ1DO	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and ITI-007.	Insomnia [7A00-7A0Z]	[21]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of ventricular arrhythmias by the combination of Amitriptyline and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[28]
Clidinium	DMUMQZ0	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and Clidinium.	Irritable bowel syndrome [DD91]	[21]
Dicyclomine	DMZSDGX	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and Dicyclomine.	Irritable bowel syndrome [DD91]	[21]
Physostigmine	DM2N0TO	Moderate	Antagonize the effect of Amitriptyline when combined with Physostigmine.	Lips/oral mucosa miscellaneous disorder [DA02]	[33]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Decreased metabolism of Amitriptyline caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[29]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Amitriptyline and Ceritinib.	Lung cancer [2C25]	[28]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Amitriptyline caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[72]
Dacomitinib	DMOH8VY	Moderate	Decreased metabolism of Amitriptyline caused by Dacomitinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[73]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Amitriptyline and Osimertinib.	Lung cancer [2C25]	[74]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Amitriptyline and Halofantrine.	Malaria [1F40-1F45]	[75]
Chloroquine	DMSI5CB	Major	Increased risk of prolong QT interval by the combination of Amitriptyline and Chloroquine.	Malaria [1F40-1F45]	[76]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Amitriptyline and Hydroxychloroquine.	Malaria [1F40-1F45]	[76]
Quinine	DMSWYF5	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Quinine.	Malaria [1F40-1F45]	[28]
Primaquine	DMWQ16I	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Primaquine.	Malaria [1F40-1F45]	[28]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[29]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Amitriptyline caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[77]
Arsenic trioxide	DM61TA4	Major	Increased risk of prolong QT interval by the combination of Amitriptyline and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[78]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Amitriptyline and Vemurafenib.	Melanoma [2C30]	[28]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and LGX818.	Melanoma [2C30]	[79]
Ethinyl estradiol	DMODJ40	Minor	Decreased metabolism of Amitriptyline caused by Ethinyl estradiol.	Menopausal disorder [GA30]	[49]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Amitriptyline and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[80]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Amitriptyline and Flibanserin.	Mood disorder [6A60-6E23]	[81]
Doxylamine	DMKOXFE	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and Doxylamine.	Morning sickness disorder [SC00]	[21]
Riluzole	DMECBWN	Minor	Decreased metabolism of Amitriptyline caused by Riluzole mediated inhibition of CYP450 enzyme.	Motor neuron disease [8B60]	[82]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Amitriptyline and Panobinostat.	Multiple myeloma [2A83]	[83]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Amitriptyline and Thalidomide.	Multiple myeloma [2A83]	[84]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Amitriptyline and Siponimod.	Multiple sclerosis [8A40]	[34]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Amitriptyline and Fingolimod.	Multiple sclerosis [8A40]	[28]
Ozanimod	DMT6AM2	Major	Additive serotonergic effects by the combination of Amitriptyline and Ozanimod.	Multiple sclerosis [8A40]	[85]
Romidepsin	DMT5GNL	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Romidepsin.	Mycosis fungoides [2B01]	[28]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Amitriptyline caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[29]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Amitriptyline and Nilotinib.	Myeloproliferative neoplasm [2A20]	[28]
Imatinib	DM7RJXL	Moderate	Decreased metabolism of Amitriptyline caused by Imatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[86]
Dasatinib	DMJV2EK	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Dasatinib.	Myeloproliferative neoplasm [2A20]	[87]
Modafinil	DMYILBE	Moderate	Decreased metabolism of Amitriptyline caused by Modafinil mediated inhibition of CYP450 enzyme.	Narcolepsy [7A20]	[34]
Phenindamine	DMDTC7R	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and Phenindamine.	Nasopharyngitis [CA00]	[21]
Droperidol	DM0DXA8	Major	Increased risk of prolong QT interval by the combination of Amitriptyline and Droperidol.	Nausea/vomiting [MD90]	[28]
Prochlorperazine	DM53SRA	Moderate	Increased plasma concentrations of Amitriptyline and Prochlorperazine due to competitive inhibition of the same metabolic pathway.	Nausea/vomiting [MD90]	[38]
Promethazine	DM6I5GR	Moderate	Increased plasma concentrations of Amitriptyline and Promethazine due to competitive inhibition of the same metabolic pathway.	Nausea/vomiting [MD90]	[38]
Rolapitant	DM8XP26	Moderate	Decreased metabolism of Amitriptyline caused by Rolapitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[88]
Cyclizine	DM9G7BS	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and Cyclizine.	Nausea/vomiting [MD90]	[21]
Palonosetron	DMBHMOX	Major	Increased risk of prolong QT interval by the combination of Amitriptyline and Palonosetron.	Nausea/vomiting [MD90]	[28]
Granisetron	DMIUW25	Major	Additive serotonergic effects by the combination of Amitriptyline and Granisetron.	Nausea/vomiting [MD90]	[28]
Ondansetron	DMOTQ1I	Major	Increased risk of prolong QT interval by the combination of Amitriptyline and Ondansetron.	Nausea/vomiting [MD90]	[28]
Thiethylperazine	DMU3IET	Moderate	Increased plasma concentrations of Amitriptyline and Thiethylperazine due to competitive inhibition of the same metabolic pathway.	Nausea/vomiting [MD90]	[38]
Bupropion	DM5PCS7	Major	Decreased metabolism of Amitriptyline caused by Bupropion mediated inhibition of CYP450 enzyme.	Nicotine use disorder [6C4A]	[28]
Entrectinib	DMMPTLH	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Entrectinib.	Non-small cell lung cancer [2C25]	[34]
Sibutramine	DMFJTDI	Major	Additive serotonergic effects by the combination of Amitriptyline and Sibutramine.	Obesity [5B80-5B81]	[89]
Lorcaserin	DMG6OYJ	Major	Additive serotonergic effects by the combination of Amitriptyline and Lorcaserin.	Obesity [5B80-5B81]	[90]
Dexfenfluramine	DMJ7YDS	Major	Additive serotonergic effects by the combination of Amitriptyline and Dexfenfluramine.	Obesity [5B80-5B81]	[23]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Amitriptyline and Levomethadyl Acetate.	Opioid use disorder [6C43]	[29]
Lofexidine	DM1WXA6	Moderate	Additive CNS depression effects by the combination of Amitriptyline and Lofexidine.	Opioid use disorder [6C43]	[29]
Apraclonidine	DMO4PVE	Moderate	Additive CNS depression effects by the combination of Amitriptyline and Apraclonidine.	Optic nerve disorder [9C40]	[91]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Rucaparib.	Ovarian cancer [2C73]	[28]
Altretamine	DMKLAYG	Moderate	Additive hypotensive effects by the combination of Amitriptyline and Altretamine.	Ovarian cancer [2C73]	[92]
Pentazocine	DM1XBHS	Moderate	Additive CNS depression effects by the combination of Amitriptyline and Pentazocine.	Pain [MG30-MG3Z]	[31]
Dextropropoxyphene	DM23HCX	Major	Additive CNS depression effects by the combination of Amitriptyline and Dextropropoxyphene.	Pain [MG30-MG3Z]	[93]
Butorphanol	DM5KYPJ	Moderate	Additive CNS depression effects by the combination of Amitriptyline and Butorphanol.	Pain [MG30-MG3Z]	[31]
Oxymorphone	DM65AGJ	Moderate	Additive CNS depression effects by the combination of Amitriptyline and Oxymorphone.	Pain [MG30-MG3Z]	[31]
Levorphanol	DMGS80V	Moderate	Additive CNS depression effects by the combination of Amitriptyline and Levorphanol.	Pain [MG30-MG3Z]	[31]
Hydromorphone	DMHP21E	Moderate	Additive CNS depression effects by the combination of Amitriptyline and Hydromorphone.	Pain [MG30-MG3Z]	[31]
Dezocine	DMJDB0Y	Moderate	Additive CNS depression effects by the combination of Amitriptyline and Dezocine.	Pain [MG30-MG3Z]	[31]
Flavoxate	DMKV4NL	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and Flavoxate.	Pain [MG30-MG3Z]	[21]
Nalbuphine	DMOSQGU	Moderate	Additive CNS depression effects by the combination of Amitriptyline and Nalbuphine.	Pain [MG30-MG3Z]	[31]
Buprenorphine	DMPRI8G	Moderate	Additive CNS depression effects by the combination of Amitriptyline and Buprenorphine.	Pain [MG30-MG3Z]	[31]
Hydrocodone	DMQ2JO5	Moderate	Additive CNS depression effects by the combination of Amitriptyline and Hydrocodone.	Pain [MG30-MG3Z]	[31]
Meperidine	DMX4GND	Major	Additive serotonergic effects by the combination of Amitriptyline and Meperidine.	Pain [MG30-MG3Z]	[23]
Oxycodone	DMXLKHV	Moderate	Additive serotonergic effects by the combination of Amitriptyline and Oxycodone.	Pain [MG30-MG3Z]	[31]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Triclabendazole.	Parasitic worm infestation [1F90]	[28]
Safinamide	DM0YWJC	Major	Additive serotonergic effects by the combination of Amitriptyline and Safinamide.	Parkinsonism [8A00]	[85]
Rasagiline	DM3WKQ4	Major	Additive serotonergic effects by the combination of Amitriptyline and Rasagiline.	Parkinsonism [8A00]	[25]
Biperiden	DME78OA	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and Biperiden.	Parkinsonism [8A00]	[21]
Procyclidine	DMHFJDT	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and Procyclidine.	Parkinsonism [8A00]	[21]
Levodopa	DMN3E57	Minor	Altered absorption of Amitriptyline due to GI dynamics variation caused by Levodopa.	Parkinsonism [8A00]	[94]
Pimavanserin	DMR7IVC	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Pimavanserin.	Parkinsonism [8A00]	[95]
Orphenadrine	DMW542E	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and Orphenadrine.	Parkinsonism [8A00]	[21]
Apomorphine	DMX38HQ	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Apomorphine.	Parkinsonism [8A00]	[28]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Amitriptyline caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[96]
Lindane	DMB8CNL	Moderate	Increased risk of lowers seizure threshold by the combination of Amitriptyline and Lindane.	Pediculosis [1G00]	[97]
Methylscopolamine	DM5VWOB	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and Methylscopolamine.	Peptic ulcer [DA61]	[21]
Famotidine	DMRL3AB	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Famotidine.	Peptic ulcer [DA61]	[34]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Amitriptyline and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[98]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Amitriptyline and Lefamulin.	Pneumonia [CA40]	[99]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Degarelix.	Prostate cancer [2C82]	[29]
ABIRATERONE	DM8V75C	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and ABIRATERONE.	Prostate cancer [2C82]	[29]
Nilutamide	DMFN07X	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Nilutamide.	Prostate cancer [2C82]	[29]
Enzalutamide	DMGL19D	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Enzalutamide.	Prostate cancer [2C82]	[29]
Flutamide	DMK0O7U	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Flutamide.	Prostate cancer [2C82]	[29]
Bicalutamide	DMZMSPF	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Bicalutamide.	Prostate cancer [2C82]	[29]
Levomepromazine	DMIKFEL	Moderate	Increased plasma concentrations of Amitriptyline and Levomepromazine due to competitive inhibition of the same metabolic pathway.	Psychotic disorder [6A20-6A25]	[38]
Fluphenazine	DMIT8LX	Moderate	Increased plasma concentrations of Amitriptyline and Fluphenazine due to competitive inhibition of the same metabolic pathway.	Psychotic disorder [6A20-6A25]	[38]
Triflupromazine	DMKFQJP	Moderate	Increased plasma concentrations of Amitriptyline and Triflupromazine due to competitive inhibition of the same metabolic pathway.	Psychotic disorder [6A20-6A25]	[38]
Sorafenib	DMS8IFC	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Sorafenib.	Renal cell carcinoma [2C90]	[28]
Gatifloxacin	DMSL679	Major	Increased risk of prolong QT interval by the combination of Amitriptyline and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[100]
Celecoxib	DM6LOQU	Moderate	Decreased metabolism of Amitriptyline caused by Celecoxib mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[101]
Cyproheptadine	DM92AH3	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and Cyproheptadine.	Rheumatoid arthritis [FA20]	[21]
Quetiapine	DM1N62C	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Quetiapine.	Schizophrenia [6A20]	[28]
Mesoridazine	DM2ZGAN	Major	Increased risk of prolong QT interval by the combination of Amitriptyline and Mesoridazine.	Schizophrenia [6A20]	[28]
Thioridazine	DM35M8J	Major	Increased risk of prolong QT interval by the combination of Amitriptyline and Thioridazine.	Schizophrenia [6A20]	[102]
Aripiprazole	DM3NUMH	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and Aripiprazole.	Schizophrenia [6A20]	[21]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Amitriptyline and Iloperidone.	Schizophrenia [6A20]	[28]
Paliperidone	DM7NPJS	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Paliperidone.	Schizophrenia [6A20]	[28]
Loxapine	DM8AI9U	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and Loxapine.	Schizophrenia [6A20]	[21]
Haloperidol	DM96SE0	Major	Increased risk of prolong QT interval by the combination of Amitriptyline and Haloperidol.	Schizophrenia [6A20]	[103]
Perphenazine	DMA4MRX	Moderate	Increased plasma concentrations of Amitriptyline and Perphenazine due to competitive inhibition of the same metabolic pathway.	Schizophrenia [6A20]	[38]
Molindone	DMAH70G	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and Molindone.	Schizophrenia [6A20]	[21]
Chlorpromazine	DMBGZI3	Moderate	Increased plasma concentrations of Amitriptyline and Chlorpromazine due to competitive inhibition of the same metabolic pathway.	Schizophrenia [6A20]	[38]
Thiothixene	DMDINC4	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and Thiothixene.	Schizophrenia [6A20]	[21]
Trifluoperazine	DMKBYWI	Moderate	Increased plasma concentrations of Amitriptyline and Trifluoperazine due to competitive inhibition of the same metabolic pathway.	Schizophrenia [6A20]	[38]
Risperidone	DMN6DXL	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and Risperidone.	Schizophrenia [6A20]	[21]
Olanzapine	DMPFN6Y	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and Olanzapine.	Schizophrenia [6A20]	[21]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Amitriptyline and Amisulpride.	Schizophrenia [6A20]	[104]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Asenapine.	Schizophrenia [6A20]	[28]
Pimozide	DMW83TP	Major	Increased risk of prolong QT interval by the combination of Amitriptyline and Pimozide.	Schizophrenia [6A20]	[29]
Sufentanil	DMU7YEL	Moderate	Additive CNS depression effects by the combination of Amitriptyline and Sufentanil.	Sensation disturbance [MB40]	[31]
Vardenafil	DMTBGW8	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Vardenafil.	Sexual dysfunction [HA00-HA01]	[28]
Armodafinil	DMGB035	Moderate	Decreased metabolism of Amitriptyline caused by Armodafinil mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[34]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Amitriptyline and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[28]
Epirubicin	DMPDW6T	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Epirubicin.	Solid tumour/cancer [2A00-2F9Z]	[28]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Amitriptyline and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[28]
Triptorelin	DMTK4LS	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[29]
Doxorubicin	DMVP5YE	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[28]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[28]
Adenosine	DMM2NSK	Moderate	Increased risk of ventricular arrhythmias by the combination of Amitriptyline and Adenosine.	Supraventricular tachyarrhythmia [BC81]	[28]
Fostamatinib	DM6AUHV	Moderate	Decreased clearance of Amitriptyline due to the transporter inhibition by Fostamatinib.	Thrombocytopenia [3B64]	[105]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Lenvatinib.	Thyroid cancer [2D10]	[28]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Amitriptyline and Cabozantinib.	Thyroid cancer [2D10]	[29]
Papaverine	DMCA9QP	Major	Increased risk of prolong QT interval by the combination of Amitriptyline and Papaverine.	Tonus and reflex abnormality [MB47]	[106]
Tizanidine	DMR2IQ4	Moderate	Additive CNS depression effects by the combination of Amitriptyline and Tizanidine.	Tonus and reflex abnormality [MB47]	[107]
Tacrolimus	DMZ7XNQ	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Tacrolimus.	Transplant rejection [NE84]	[28]
Atropine	DMEN6X7	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and Atropine.	Unspecific substance harmful effect [NE6Z]	[21]
Astemizole	DM2HN6Q	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Astemizole.	Vasomotor/allergic rhinitis [CA08]	[28]
Triprolidine	DM7SWIA	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and Triprolidine.	Vasomotor/allergic rhinitis [CA08]	[21]
Methdilazine	DMAUHQX	Moderate	Increased plasma concentrations of Amitriptyline and Methdilazine due to competitive inhibition of the same metabolic pathway.	Vasomotor/allergic rhinitis [CA08]	[38]
Carbinoxamine	DMCT31R	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and Carbinoxamine.	Vasomotor/allergic rhinitis [CA08]	[21]
Trimeprazine	DMEMV9D	Moderate	Increased plasma concentrations of Amitriptyline and Trimeprazine due to competitive inhibition of the same metabolic pathway.	Vasomotor/allergic rhinitis [CA08]	[108]
Brompheniramine	DMFOVSD	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and Brompheniramine.	Vasomotor/allergic rhinitis [CA08]	[21]
Dexbrompheniramine	DMKVWGE	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and Dexbrompheniramine.	Vasomotor/allergic rhinitis [CA08]	[21]
Cetirizine	DMOMP9U	Moderate	Additive CNS depression effects by the combination of Amitriptyline and Cetirizine.	Vasomotor/allergic rhinitis [CA08]	[109]
Acrivastine	DMTIGA0	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[21]
Azatadine	DMZ80SB	Moderate	Additive anticholinergic effects by the combination of Amitriptyline and Azatadine.	Vasomotor/allergic rhinitis [CA08]	[21]
Procainamide	DMNMXR8	Major	Increased risk of prolong QT interval by the combination of Amitriptyline and Procainamide.	Ventricular tachyarrhythmia [BC71]	[28]
Propafenone	DMPIBJK	Moderate	Decreased metabolism of Amitriptyline caused by Propafenone mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[110]
Flecainide	DMSQDLE	Moderate	Increased risk of prolong QT interval by the combination of Amitriptyline and Flecainide.	Ventricular tachyarrhythmia [BC71]	[110]
Amiodarone	DMUTEX3	Major	Increased risk of prolong QT interval by the combination of Amitriptyline and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[28]
-----------


⏷ Show the Full List of 264 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
D&C red no. 27	E00381	83511	Colorant
D&C red no. 30	E00456	3000709	Colorant
D&C red no. 33	E00261	19116	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Hydrazine yellow	E00409	164825	Colorant
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Calcium sulfate anhydrous	E00303	24497	Desiccant; Diluent
Carmellose sodium	E00625	Not Available	Disintegrant
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Lithol rubin BCA	E00607	135423095	Colorant
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Soybean lecithin	E00637	Not Available	Other agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
--------------------


⏷ Show the Full List of 26 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Amitriptyline 10 mg tablet	10 mg	Oral Tablet	Oral
Amitriptyline 100 mg tablet	100 mg	Oral Tablet	Oral
Amitriptyline 150 mg tablet	150 mg	Oral Tablet	Oral
Amitriptyline 25 mg tablet	25 mg	Oral Tablet	Oral
Amitriptyline 50 mg tablet	50 mg	Oral Tablet	Oral
Amitriptyline 75 mg tablet	75 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 200).
2	Amitriptyline FDA Label
3	BDDCS applied to over 900 drugs
4	Norwegian Food Safety Authority: Methyl salicylate risk review
5	Bryson HM, Wilde MI: Amitriptyline. A review of its pharmacological properties and therapeutic use in chronic pain states. Drugs Aging. 1996 Jun;8(6):459-76. doi: 10.2165/00002512-199608060-00008.
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
8	ABCB1 gene variants influence tolerance to selective serotonin reuptake inhibitors in a large sample of Dutch cases with major depressive disorder. Pharmacogenomics J. 2013 Aug;13(4):349-53.
9	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
10	Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
11	Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22.
12	Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem Biol Interact. 2008 May 9;173(1):59-67.
13	Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19 and 3A4. J Clin Pharmacol. 1998 Feb;38(2):112-21.
14	Cytochromes P450 mediating the N-demethylation of amitriptyline. Br J Clin Pharmacol. 1997 Feb;43(2):137-44.
15	Liquid chromatography-tandem mass spectrometry method for measurement of nicotine N-glucuronide: a marker for human UGT2B10 inhibition. J Pharm Biomed Anal. 2011 Jul 15;55(5):964-71.
16	A study on CYP2C19 and CYP2D6 polymorphic effects on pharmacokinetics and pharmacodynamics of amitriptyline in healthy Koreans. Clin Transl Sci. 2017 Mar;10(2):93-101.
17	The genetic profiles of CYP1A1, CYP1A2 and CYP2E1 enzymes as susceptibility factor in xenobiotic toxicity in Turkish population. Saudi Pharm J. 2017 Feb;25(2):294-297.
18	Effects of cytochrome b(5) on drug oxidation activities of human cytochrome P450 (CYP) 3As: similarity of CYP3A5 with CYP3A4 but not CYP3A7. Biochem Pharmacol. 2003 Dec 15;66(12):2333-40.
19	Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37.
20	The xenobiotic inhibitor profile of cytochrome P4502C8. Br J Clin Pharmacol. 2000 Dec;50(6):573-80.
21	Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
22	Aranow AB, Hudson JI, Pope HG, et al "Elevated antidepressant plasma levels after addition of fluoxetine." Am J Psychiatry 146 (1989): 911-3. [PMID: 2787124]
23	Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406. [PMID: 1530079]
24	Albers LJ, Reist C, Helmeste D, Vu R, Tang SW "Paroxetine shifts imipramine metabolism." Psychiatry Res 59 (1996): 189-96. [PMID: 8930024]
25	Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20. [PMID: 15784664]
26	Bhatara VS, Magnus RD, Paul KL, Preskorn SH "Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms." Ann Pharmacother 32 (1998): 432-6. [PMID: 9562139]
27	Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
28	Canadian Pharmacists Association.
29	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
30	Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
31	Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
32	Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
33	Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
34	Cerner Multum, Inc. "Australian Product Information.".
35	Hollingshead LM, Faulds D, Fitton A "Bepridil. A review of its pharmacological properties and therapeutic use in stable angina pectoris." Drugs 44 (1992): 835-57. [PMID: 1280569]
36	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
37	Product Information. Onfi (clobazam). Lundbeck Inc, Deerfield, IL.
38	Bock JL, Nelson JC, Gray S, Jatlow PI "Desipramine hydroxylation: variability and effect of antipsychotic drugs." Clin Pharmacol Ther 33 (1983): 322-8. [PMID: 6130865]
39	Burke MS, Josephson A, Lightsey A "Combined methylphenidate and imipramine complication." J Am Acad Child Adolesc Psychiatry 34 (1995): 403-4. [PMID: 7751253]
40	Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
41	Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77. [PMID: 11103749]
42	Bergeron L, Boule M, Perreault S "Serotonin toxicity associated with concomitant use of linezolid." Ann Pharmacother 39 (2005): 956-61. [PMID: 15827071]
43	Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
44	Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
45	Multum Information Services, Inc. Expert Review Panel.
46	Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
47	Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
48	Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
49	Edelbroek PM, Zitman FG, Knoppert-van der Klein EA, van Putten PM, de Wolff FA "Therapeutic drug monitoring of amitriptyline: impact of age, smoking and contraceptives on drug and metabolite levels in bulimic women." Clin Chim Acta 165 (1987): 177-87. [PMID: 3652444]
50	Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
51	Ciraulo DA, Alderson LM, Chapron DJ, Jaffe JH, Subbarao B, Kramer PA "Imipramine disposition in alcoholics." J Clin Psychopharmacol 2 (1982): 2-7. [PMID: 7068940]
52	Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50. [PMID: 1968472]
53	Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
54	Fogelson DL "Fenfluramine and the cytochrome P450 system." Am J Psychiatry 154 (1997): 436-7. [PMID: 9054800]
55	Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
56	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
57	Brosen K, Kragh-Sorensen P "Concomitant intake of nortriptyline and carbamazepine." Ther Drug Monit 15 (1993): 258-60. [PMID: 8333008]
58	Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
59	Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ.
60	Dorsey ST, Biblio LA "Prolonged QT interval and torsades de pointes caused by the combination of fluconazole and amitriptyline." Am J Emerg Med 18 (2000): 227-9. [PMID: 10750939]
61	AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL "Investigation of terbinafine as a CYP2D6 inhibitor in vivo." Clin Pharmacol Ther 65 (1999): 465-72. [PMID: 10340911]
62	Abernethy DR, Greenblatt DJ, Shader RI "Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability." J Pharmacol Exp Ther 229 (1984): 702-5. [PMID: 6726654]
63	Gram LF, Kofod B, Christiansen J, Rafaelsen OJ "Imipramine metabolism: pH-dependent distribution and urinary excretion." Clin Pharmacol Ther 12 (1971): 239-44. [PMID: 5554940]
64	Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
65	Eap CB, Bender S, Gastpar M, et al "Steady state plasma levels of the enantiomers of trimipramine and its metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-phenotyped patients." Ther Drug Monit 22 (2000): 209-14. [PMID: 10774635]
66	Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
67	Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
68	Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
69	Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
70	Product Information. Norvir (ritonavir). Abbott Pharmaceutical, Abbott Park, IL.
71	Hermann DJ, Krol TF, Dukes GE, et al "Comparison of verapamil, diltiazem, and labetalol on the bioavailability and metabolism of imipramine." J Clin Pharmacol 32 (1992): 176-83. [PMID: 1613128]
72	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
73	Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
74	Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
75	Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
76	Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
77	Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
78	Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
79	Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
80	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
81	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
82	Product Information. Rilutek (riluzole). Rhone-Poulenc Rorer, Collegeville, PA.
83	Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
84	Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
85	Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311. [PMID: 2365671]
86	Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
87	Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
88	Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
89	Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5. [PMID: 9861909]
90	Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
91	Product Information. Iopidine (apraclonidine). Alcon Laboratories Inc, Fort Worth, TX.
92	Bruckner HW, Schleifer SJ "Orthostatic hypotension as a complication of hexamethylmelamine antidepressant interaction." Cancer Treat Rep 67 (1983): 516. [PMID: 6406063]
93	Tofanetti O, Albiero L, Galatulas I, Genovese E "Enhancement of propoxyphene-induced analgesia by doxepin." Psychopharmacology (Berl) 51 (1977): 213-5. [PMID: 402676]
94	Morgan JP, Rivera-Calimlim L, Messiha F, Sundaresan PR, Trabert N "Imipramine-mediated interference with levodopa absorption from the gastrointestinal tract in man." Neurology 25 (1975): 1029-34. [PMID: 1237820]
95	Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
96	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
97	Matsuoka LY "Convulsions following application of gamma benzene hexachloride." J Am Acad Dermatol 5 (1981): 98-9. [PMID: 6168673]
98	Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
99	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
100	Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
101	Product Information. Celebrex (celecoxib). Searle, Chicago, IL.
102	Bluhm RE, Wilkinson GR, Shelton R, Branch RA "Genetically determined drug-metabolizing activity and desipramine- associated cardiotoxicity: a case report." Clin Pharmacol Ther 53 (1993): 89-95. [PMID: 8422746]
103	Alter P, Tontsch D, Grimm W "Doxepin-induced torsade de pointes tachycardia." Ann Intern Med 135 (2001): 384-5. [PMID: 11529713]
104	Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
105	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
106	Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
107	Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.
108	Lee BS "Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs." J Clin Psychiatry 47 (1986): 571. [PMID: 3771507]
109	Product Information. Zyrtec (cetirizine). Pfizer US Pharmaceuticals, New York, NY.
110	Katz MR "Raised serum levels of desipramine with the antiarrhythmic propafenone ." J Clin Psychiatry 52 (1991): 432-3. [PMID: 1938981]